Prospective Observational Study to Assess the Association between Glycemic Control, Lipid Profile and C-reactive Protein in Adults with Type 2 Diabetes Mellitus
Authors/Creators
- 1. Senior Resident, Department of General Medicine, Seikh Bhikhari Medical College, Hazaribagh, Jharkhand, India
Description
Aim: The aim of this study to determine the Correlation between glycemic control, lipid profile and C-reactive protein in adults with type 2 diabetes mellitus done tertiary care hospital of Jharkhand region, India. Methods: This prospective observational study was carried out in the Department of General medicine, Seikh Bhikhari Medical College, Hazaribgah, Jharkhand, India for 1 year. The patients above 28 years with fasting venous blood glucose value equal or more than 100 mg/dl and postprandial glucose >140 mg/dl were include in this study. FBS and PPBS, CRP (immunoturbidimetric method), and HbA1C (ion exchange chromatography using HPLC) lipid profile samples were drawn at entry and at subsequent follow-up with a minimum gap of 3-6 months. Results: total cholesterol was compared to CRP. Number of patients with total cholesterol <100 was 5, 100-200 were 35, 200-300 were 22 with mean CRP of 1.79, 0.82, 2.88. There was a significant positive correlation between CRP and total cholesterol (p<0.05). LDL cholesterol was compared with CRP. Patients with LDL cholesterol <60 were 12, between 60-80 were 26, between 80-100 were 15, between 100-120 were 24, between 120-140 was 1, >140 were 12 with mean CRP levels of 1.86, 0.85, 1.83, 0.76, 1.35, 2.28. There was no significant correlation between CRP and LDL cholesterol (p>0.05). HDL cholesterol was compared with CRP. Patients with HDL cholesterol between 0-20 were 3, between 20-40 were 43, between 40-60 were 41 and HDL cholesterol >60 were 3 with mean CRP levels of 2.15, 1.42, 1.23, 1.17, respectively. There was a negative correlation between HDL cholesterol and CRP triglyceride levels were compared with CRP. Patients with triglyceride levels between 100-200 were 45, between 200-300 were 30, between 300-400 were 8, between 400-500 was 3 and with levels >500 were 4 with mean CRP levels of 0.72, 0.85, 1.85, 2.46, 2.46, respectively. There was significant positive correlation between CRP and triglyceride levels (p<0.05). patients with HbA1C <7 were 15 between 7-9 were 22, between 9-10 were 20, HbA1C >10 were 33 with mean CRP of 0.48, 0.66, 1.55, 2.29, respectively. There was significant correlation between CRP and HbA1C (p<0.05). Conclusion: We concluded that the CRP is an additional marker of better glycaemic control and also correlates with the dyslipidaemia profile seen in type 2 diabetes mellitus.
Abstract (English)
Aim: The aim of this study to determine the Correlation between glycemic control, lipid profile and C-reactive protein in adults with type 2 diabetes mellitus done tertiary care hospital of Jharkhand region, India. Methods: This prospective observational study was carried out in the Department of General medicine, Seikh Bhikhari Medical College, Hazaribgah, Jharkhand, India for 1 year. The patients above 28 years with fasting venous blood glucose value equal or more than 100 mg/dl and postprandial glucose >140 mg/dl were include in this study. FBS and PPBS, CRP (immunoturbidimetric method), and HbA1C (ion exchange chromatography using HPLC) lipid profile samples were drawn at entry and at subsequent follow-up with a minimum gap of 3-6 months. Results: total cholesterol was compared to CRP. Number of patients with total cholesterol <100 was 5, 100-200 were 35, 200-300 were 22 with mean CRP of 1.79, 0.82, 2.88. There was a significant positive correlation between CRP and total cholesterol (p<0.05). LDL cholesterol was compared with CRP. Patients with LDL cholesterol <60 were 12, between 60-80 were 26, between 80-100 were 15, between 100-120 were 24, between 120-140 was 1, >140 were 12 with mean CRP levels of 1.86, 0.85, 1.83, 0.76, 1.35, 2.28. There was no significant correlation between CRP and LDL cholesterol (p>0.05). HDL cholesterol was compared with CRP. Patients with HDL cholesterol between 0-20 were 3, between 20-40 were 43, between 40-60 were 41 and HDL cholesterol >60 were 3 with mean CRP levels of 2.15, 1.42, 1.23, 1.17, respectively. There was a negative correlation between HDL cholesterol and CRP triglyceride levels were compared with CRP. Patients with triglyceride levels between 100-200 were 45, between 200-300 were 30, between 300-400 were 8, between 400-500 was 3 and with levels >500 were 4 with mean CRP levels of 0.72, 0.85, 1.85, 2.46, 2.46, respectively. There was significant positive correlation between CRP and triglyceride levels (p<0.05). patients with HbA1C <7 were 15 between 7-9 were 22, between 9-10 were 20, HbA1C >10 were 33 with mean CRP of 0.48, 0.66, 1.55, 2.29, respectively. There was significant correlation between CRP and HbA1C (p<0.05). Conclusion: We concluded that the CRP is an additional marker of better glycaemic control and also correlates with the dyslipidaemia profile seen in type 2 diabetes mellitus.
Files
IJPCR,Vol13,Issue6,Article78.pdf
Files
(145.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:465b546ac16a4275b7b47801a8f143e6
|
145.6 kB | Preview Download |
Additional details
Dates
- Accepted
-
2021-11-27
Software
- Repository URL
- http://impactfactor.org/PDF/IJPCR/13/IJPCR,Vol13,Issue6,Article78.pdf
- Development Status
- Active
References
- 1. Frier BM, Fisher M. Diabetes mellitus. In: Colledge NR, Walker BR, Ralston SH, editors. Davidsons's Principles and Practice of Medicine. 21st ed. New York, NY, USA: Churchill Livingstone Elsevier; 2010. 2. International Diabetes Federation. IDF Diabetes Atlas. 6th ed, 2013. Available from: http://www.idf.org/sites/default/files/E N_6E_Atlas_Full_0.pdf. Accessed June 25, 2015. 3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. 4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11): e442. 5. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123(3 Suppl): S3–S11. 6. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811–822. 7. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5):737–747. 8. Lloyd-Jones D, Adams R, Carnethon M, et al. heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3): e21–e181. 9. Kvan E, Pettersen KI, Sandvik L, Reikvam A. High mortality in diabetic patients with acute myocardial infarction: cardiovascular comorbidities contribute most to the high risk. Int J Cardiol. 2007;121(2):184– 188. 10. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2: S14– S21. 11. Mendis S, Puska P, Norrving B, editors. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: World Health Organization; 2011. 12. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990;20(3):129–147. 13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. 14. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovasculardisease risk. J Am Coll Cardiol. 2007;50(12):1115–1122. 15. Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA. Harper's Illustrated Biochemistry. 28th ed. New York, NY, USA: McGraw-Hill Companies; 2009. 16. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–1565. 17. Su SC, Pei D, Hsieh CH, Hsiao FC, Wu CZ, Hung YJ. Circulating proinflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol. 2011;48(2):113–119. 18. Rekeneire N, Peila R, Ding J, et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care. 2006;29(8):1902–1908 19. King DE, Mainous AG, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003; 26:1535- 9. 20. Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of serum C- reactive protein level with sex-specific type 2 diabetes risk: a prospective finnish study. J Clin Endocrinol Metabol. 2009;94(6):2099-105. 21. Williams MJ, Williams SM, Milne BJ, Hancox RJ, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Inter J Obes. 2004; 28:998-1003. 22. Michelle A, Robert J, Paul MP. Plasma concentration of c-reactive protein and the calculated framingham coronary heart disease risk score. Circulat. 2003; 108:161-5. 23. Steven E, Murat T, Paul S, Tim C, Sasiela WJ, John T, et al. C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352:29-38. 24. Takiko Y, Atura T, Mitsuo F, Yoshikatsu N, Shoichiro N, Minako O, et al. Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Diab Res Clin Pract. 2007; 75:2-6. 25. Ana ML, Eridan S, Carol LF, Agnaluce M, Angela H, Luis A. Association between elevated serum c- reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care. 2006; 29:424-6